{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:24:15Z","timestamp":1788542655856,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00417-017-3692-z","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T23:11:15Z","timestamp":1498605075000},"page":"1543-1550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye"],"prefix":"10.1007","volume":"255","author":[{"given":"Masahiko","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Nunome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"3692_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"3692_CR2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"3692_CR3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802\u2013809","journal-title":"Ophthalmology"},{"key":"3692_CR4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789\u2013801","journal-title":"Ophthalmology"},{"key":"3692_CR5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ophtha.2008.09.046","volume":"116","author":"T Ueta","year":"2009","unstructured":"Ueta T, Yanagi Y, Tamaki Y et al (2009) Cerebrovascular accidents in ranibizumab. Ophthalmology 116:362","journal-title":"Ophthalmology"},{"key":"3692_CR6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349","journal-title":"Br J Ophthalmol"},{"key":"3692_CR7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","volume":"128","author":"LH Curtis","year":"2010","unstructured":"Curtis LH, Hammill BG, Schulman KA et al (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128:1273","journal-title":"Arch Ophthalmol"},{"key":"3692_CR8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajo.2015.06.011","volume":"160","author":"MB Schlenker","year":"2015","unstructured":"Schlenker MB, Thiruchelvam D, Redelmeier DA (2015) Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism. Am J Ophthalmol 160:569\u2013580","journal-title":"Am J Ophthalmol"},{"key":"3692_CR9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","volume":"132","author":"M Thulliez","year":"2014","unstructured":"Thulliez M, Angoulvant D, Le Lez ML et al (2014) Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132:1317\u20131326","journal-title":"JAMA Ophthalmol"},{"key":"3692_CR10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2016.02.046","volume":"123","author":"JW Kitchens","year":"2016","unstructured":"Kitchens JW, Do DV, Boyer DS et al (2016) Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials. Ophthalmology 123:1511\u20131520","journal-title":"Ophthalmology"},{"key":"3692_CR11","first-page":"3825","volume":"35","author":"Y Tamaki","year":"1994","unstructured":"Tamaki Y, Araie M, Kawamoto E et al (1994) Noncontact, two-dimensional measurement of retinal microcirculation using laser speckle phenomenon. Invest Ophthalmol Vis Sci 35:3825\u20133834","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0021-5155(97)00054-3","volume":"41","author":"Y Tamaki","year":"1997","unstructured":"Tamaki Y, Araie M, Tomita K et al (1997) Effect of topical timolol on tissue circulation in optic nerve head. Jpn J Ophthalmol 41:297\u2013304","journal-title":"Jpn J Ophthalmol"},{"key":"3692_CR13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1167\/iovs.09-4422","volume":"52","author":"M Nagahara","year":"2011","unstructured":"Nagahara M, Tamaki Y, Tomidokoro A et al (2011) In vivo measurement of blood velocity in human major retinal vessels using the laser speckle method. Invest Ophthalmol Vis Sci 52:87\u201392","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12886-016-0211-7","volume":"16","author":"D Nagasato","year":"2016","unstructured":"Nagasato D, Mitamura Y, Semba K, Akaiwa K, Nagasawa T, Yoshizumi Y, Tabuchi H, Kiuchi Y (2016) Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series. BMC Ophthalmol 16:36","journal-title":"BMC Ophthalmol"},{"key":"3692_CR15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1755-3768.2009.01586.x","volume":"8","author":"T Sugiyama","year":"2010","unstructured":"Sugiyama T, Araie M, Riva CE et al (2010) Use of laser speckle flowgraphy in ocular blood flow research. Acta Ophthalmol 8:723\u2013729","journal-title":"Acta Ophthalmol"},{"key":"3692_CR16","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1167\/iovs.08-2882","volume":"50","author":"Y Liang","year":"2009","unstructured":"Liang Y, Downs JC, Fortune B et al (2009) Impact of systemic blood pressure on the relationship between intraocular pressure and blood flow in the optic nerve head of nonhuman primates. Invest Ophthalmol Vis Sci 50:2154\u20132160","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR17","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.1167\/iovs.12-10911","volume":"53","author":"L Wang","year":"2012","unstructured":"Wang L, Cull GA, Piper C et al (2012) Anterior and posterior optic nerve head blood flow in nonhuman primate experimental glaucoma model measured by laser speckle imaging technique and microsphere method. Invest Ophthalmol Vis Sci 53:8303\u20138309","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2415-14-73","volume":"14","author":"K Hirooka","year":"2014","unstructured":"Hirooka K, Saito W, Hashimoto Y et al (2014) Increased macular choroidal blood flow velocity and decreased choroidal thickness with regression of punctate inner choroidopathy. BMC Ophthalmol 14:73","journal-title":"BMC Ophthalmol"},{"key":"3692_CR19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.exer.2012.12.003","volume":"108","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Sugiyama T, Tokushige H, Maeno T, Nakazawa T, Ikeda T, Araie M (2013) Comparison of CCD-equipped laser speckle flowgraphy with hydrogen gas clearance method in the measurement of optic nerve head microcirculation in rabbits. Exp Eye Res 108:10\u201315","journal-title":"Exp Eye Res"},{"key":"3692_CR20","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.1167\/iovs.12-10911","volume":"53","author":"L Wang","year":"2012","unstructured":"Wang L, Cull GA, Piper C, Burgoyne CF, Fortune B (2012) Anterior and posterior optic nerve head blood flow in nonhuman primate experimental glaucoma model measured by laser speckle imaging technique and microsphere method. Invest Ophthalmol Vis Sci 53:8303\u20138309","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR21","first-page":"1119","volume":"8","author":"F Nitta","year":"2014","unstructured":"Nitta F, Kunikata H, Aizawa N et al (2014) The effect of intravitreal bevacizumab on ocular blood flow in diabetic retinopathy and branch retinal vein occlusion as measured by laser speckle flowgraphy. Clin Ophthalmol 8:1119\u20131127","journal-title":"Clin Ophthalmol"},{"key":"3692_CR22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","volume":"26","author":"C Haritoglou","year":"2006","unstructured":"Haritoglou C, Kook D, Neubauer A et al (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999\u20131005","journal-title":"Retina"},{"key":"3692_CR23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archopht.124.9.1365","volume":"124","author":"SM Friedlander","year":"2006","unstructured":"Friedlander SM, Welch RM (2006) Vanishing disc neovascularization folowing intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol 124:1365","journal-title":"Arch Ophthalmol"},{"key":"3692_CR24","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/j.1755-3768.2010.02075.x","volume":"89","author":"Y Toklu","year":"2011","unstructured":"Toklu Y, Cakmak HB, Raza S et al (2011) Short-term effects of intravitreal bevacizumab (Avastin\u00ae) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmol 89:e41\u2013e45","journal-title":"Acta Ophthalmol"},{"key":"3692_CR25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/15569527.2013.796478","volume":"33","author":"M Shahin","year":"2014","unstructured":"Shahin M, Gad MA, Hamza W (2014) Impact of intravitreal triamcinolone acetonide versus intravitreal bevacizumab on retrobulbar hemodynamic in patients with diabetic macular edema. Cutan Ocul Toxicol 33:49\u201353","journal-title":"Cutan Ocul Toxicol"},{"key":"3692_CR26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3928\/15428877-20101124-11","volume":"41","author":"H Enaida","year":"2010","unstructured":"Enaida H, Okamoto K, Fujii H et al (2010) LSFG findings of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging 41:e1\u2013e3","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"3692_CR27","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277\u20132285","journal-title":"JAMA"},{"key":"3692_CR28","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M, Fink LM, Elice F et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865\u20134873","journal-title":"J Clin Oncol"},{"key":"3692_CR29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ajo.2004.01.008","volume":"137","author":"RF Degenring","year":"2004","unstructured":"Degenring RF, Jonas JB (2004) Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137:1142\u20131143","journal-title":"Am J Ophthalmol"},{"key":"3692_CR30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0002-8703(85)90070-5","volume":"110","author":"M Chiariello","year":"1985","unstructured":"Chiariello M, Indolfi C, Cotecchia MR et al (1985) Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J 110:529\u2013534","journal-title":"Am Heart J"},{"key":"3692_CR31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/hr.2010.122","volume":"33","author":"R Bouchi","year":"2010","unstructured":"Bouchi R, Babazono T, Yoshida N et al (2010) Silent cerebral infarction is associated with the development and progression of nephropathy in patients with type 2 diabetes. Hypertens Res 33:1000\u20131003","journal-title":"Hypertens Res"},{"key":"3692_CR32","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/IAE.0b013e31825db6ba","volume":"32","author":"NM Bressler","year":"2012","unstructured":"Bressler NM, Boyer DS, Williams DF et al (2012) Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 32:1821\u20131828","journal-title":"Retina"},{"key":"3692_CR33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","volume":"134","author":"RL Avery","year":"2016","unstructured":"Avery RL, Gordon GM (2016) Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 134:21\u201329","journal-title":"JAMA Ophthalmol"},{"key":"3692_CR34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","volume":"98","author":"S Julien","year":"2014","unstructured":"Julien S, Biesemeier A, Taubitz T et al (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98:813\u2013825","journal-title":"Br J Ophthalmol"},{"key":"3692_CR35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/IAE.0000000000000428","volume":"35","author":"H Terasaki","year":"2015","unstructured":"Terasaki H, Sakamoto T, Shirasawa M et al (2015) Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro. Retina 35:1007\u20131015","journal-title":"Retina"},{"key":"3692_CR36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908","journal-title":"N Engl J Med"},{"key":"3692_CR37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193\u20131203","journal-title":"N Engl J Med"},{"key":"3692_CR38","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641","journal-title":"Br J Ophthalmol"},{"key":"3692_CR39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00417-014-2717-0","volume":"252","author":"I Yoshida","year":"2014","unstructured":"Yoshida I, Shiba T, Taniguchi H et al (2014) Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252:1483\u20131489","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3692_CR40","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ajo.2014.06.009","volume":"158","author":"X Wang","year":"2014","unstructured":"Wang X, Sawada T, Sawada O et al (2014) Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 158:738\u2013744","journal-title":"Am J Ophthalmol"},{"key":"3692_CR41","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ophtha.2014.05.012","volume":"121","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Yao Z, Kaila N et al (2014) Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology 121:2237\u20132246","journal-title":"Ophthalmology"},{"key":"3692_CR42","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1167\/iovs.10-6862","volume":"52","author":"JB Christoforidis","year":"2011","unstructured":"Christoforidis JB, Carlton MM, Knopp MV, Hinkle GH (2011) PET\/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci 52:5899\u20135903","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR43","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","volume":"54","author":"L Xu","year":"2013","unstructured":"Xu L, Lu T, Tuomi L et al (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616\u20131624","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3692_CR44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3928\/23258160-20160419-12","volume":"47","author":"CM Calvo","year":"2016","unstructured":"Calvo CM, Sridhar J, Shahlaee A et al (2016) Reduction of diabetic macular edema in the untreated fellow eye following intravitreal injection of aflibercept. Ophthalmic Surg Lasers Imaging Retina 47:474\u2013476","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"3692_CR45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/eye.2014.94","volume":"28","author":"J Hanhart","year":"2014","unstructured":"Hanhart J, Tiosano L, Averbukh E, Banin E, Hemo I, Chowers I (2014) Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye (Lond) 28:646\u2013653","journal-title":"Eye (Lond)"},{"key":"3692_CR46","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1089\/jop.2013.0049","volume":"29","author":"B Bakbak","year":"2013","unstructured":"Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S (2013) Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 29:728\u2013732","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-017-3692-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3692-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3692-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T05:29:21Z","timestamp":1692854961000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-017-3692-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3692"],"URL":"https:\/\/doi.org\/10.1007\/s00417-017-3692-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}